Hypomethylators Flashcards
(25 cards)
What drugs are in the Hypomethylator class?
Drugs in this class are:
- Azacitidine
- Decitabine
What is the brand name of Azacitidine?
The brand name of this generic drug is:
- Vidaza (IV, SubQ)
- Onureg (Oral)
What is the brand name of Decitabine?
The brand name of this generic drug is:
- Dacogen
What is the generic of name of Vidaza?
The generic name of this brand name drug is:
- Azacitidine
What is the generic of name of Onureg?
The generic name of this brand name drug is:
- Azacitidine
What is the generic of name of Dacogen?
The generic name of this brand name drug is:
- Decitabine
What are the main indications for use of Azacitidine?
The main indications of this drug are:
- AML
- MDS
What are the main indications for use of Decitabine?
The main indications of this drug are:
- AML
- MDS
What are the main/common indications of the Hypomethylator class?
The main/common indications of this drug class are:
- AML
- MDS
What is the class and MOA of Azacitidine?
This drug in the following class:
- Hypomethylator
This drug’s MOA is as follows:
- Methylation (via methyltransferase) of tumor suppressor genes can contribute to the growth and survival of the cancer. Hypomethylating agents prevent DNA methylation by inhibiting methyltransferase, thus allowing for tumor suppressor gene expression which thus inhibits cancer growth.
What is the class and MOA of Decitabine?
This drug in the following class:
- Hypomethylator
This drug’s MOA is as follows:
- Methylation (via methyltransferase) of tumor suppressor genes can contribute to the growth and survival of the cancer. Hypomethylating agents prevent DNA methylation by inhibiting methyltransferase, thus allowing for tumor suppressor gene expression which thus inhibits cancer growth.
What is the emetic potential of Azacitidine?
The emetic potential of this drug is:
- Moderate
Describe the emetic potential of Decitabine.
The emetic potential of this drug is:
- Minimal
What drugs in the Hypomethylator class have a high emetic potential?
Drugs in the class with a high emetic potential are:
- None, N/A
What drugs in the Hypomethylator class have a moderate emetic potential?
Drugs in the class with a moderate emetic potential are:
- Azacitidine
What drugs in the Hypomethylator class have a low emetic potential?
Drugs in the class with a low emetic potential are:
- None, N/A
What drugs in the Hypomethylator class have a minimal emetic potential?
Drugs in the class with a minimal emetic potential are:
- Decitabine
Describe the extravasation risk and management strategies for Azacitidine.
The extravasation risk and management strategies for this drug are as follows:
- None, N/A
Describe the extravasation risk and management strategies for Decitabine.
The extravasation risk and management strategies for this drug are as follows:
- None, N/A
Describe the extravasation risk and management strategies for the Hypomethylator class.
The extravasation risk and management strategies for this drug class are as follows:
- None, N/A
Describe the distribution of the Hypomethylator class.
The distribution of this class is described as follows:
- Hypomethylating agents do not cross the blood brain barrier and will have limited utility in treating patients with central nervous system disease.
Describe the administration of Azacitidine.
The administration of this drug is described as follows:
- Vidaza is given IV or SubQ
- Onureg is given orally
What are the notable/common ADRs of the Hypomethylator class?
The notable/common ADRs of this drug class are:
- Bone marrow suppression
Describe the strategy and rationale for management of bone marrow suppression caused by hypomethylators.
The strategy and rationale for management of this condition caused by this drug are:
- This is the major side effect of the hypomethylators, however it can be difficult to determine if it is from the chemotherapy or the patient’s disease.
- In many cases, we will treat through it for the first few cycles of therapy (due to the long time to response of hypomethylators) but patients with this after 3-4 months of therapy may need a bone marrow biopsy to rule out relapsed disease.
